Table 4.
Univariate and Cox regression model for 30-day mortality
| Variable | Survival (n = 254) |
No survival (n = 139) |
Pa | HR (95% CI) | Pb |
|---|---|---|---|---|---|
| Age, years | 54.0 (48.0–63.0) | 59.0 (48.0–68.0) | < 0.001 | ||
| ICU admission, n (%) | 229 (90.2%) | 132 (95.0%) | 0.096 | ||
| Mechanical ventilation | 163 (64.2%) | 106 (76.3%) | 0.014 | ||
| SOFA score | 8.0 (5.0–10.0) | 9.0 (7.0–12.0) | < 0.001 | ||
| APACHE II score | 17.0 (11.0–21.8) | 19.0 (14.0–24.0) | 0.002 | ||
| Comorbidities | |||||
| Diabetes | 74 (29.1%) | 53 (38.1%) | 0.068 | ||
| Heart disease | 46 (18.1%) | 51 (36.7%) | < 0.001 | 1.92 (1.31–2.83) | 0.001 |
| Sepsis | 106 (41.7%) | 80 (57.6%) | 0.003 | ||
| Septic shock | 75 (29.5%) | 78 (56.1%) | < 0.001 | 2.29 (1.54–3.40) | < 0.001 |
| Laboratory data | |||||
| GFR, mL/min·1.73m2 | 103.1 (80.6–118.9) | 86.5 (41.8–110.9) | < 0.001 | 0.99 (0.99–1.0) | 0.001 |
| Albumin, g/L | 30.2 (27.3–34.9) | 29.2 (26.6–32.9) | 0.021 | ||
| Platelets, 109/L | 178.0(84.3–294.8) | 127.0 (71.0–194.0) | < 0.001 | ||
| C-reactive protein, μg/L | 68.1 (30.4–127.2) | 107.5 (47.3–159.9) | 0.001 | ||
| Procalcitonin, ng/mL | 0.7 (0.3–3.4) | 1.4 (0.6–5.9) | < 0.001 | ||
| Concomitant nephrotoxic drugs | |||||
| Vancomycin | 43 (16.9%) | 40 (28.8%) | 0.006 | ||
| Furosemide | 89 (35.0%) | 65 (47.1%) | 0.020 | ||
| Vasoactive drugs | 110 (43.8%) | 85 (63.0%) | < 0.001 | ||
| Use of nephrotoxic drugs | 166 (65.4%) | 123 (88.5%) | < 0.001 | 2.70 (1.48–4.93) | 0.001 |
| AKI | 63 (24.8%) | 51 (36.7%) | 0.013 | ||
HR hazard ratio; CI confidence interval; and GFR glomerular filtration rate
aderived from univariate analysis
bderived from Cox regression analysis